肝脏 ›› 2022, Vol. 27 ›› Issue (8): 908-911.

• 其他肝病 • 上一篇    下一篇

Crigler-Najjar综合征Ⅱ型患者的临床、肝脏病理特征及突变基因分析

徐静, 董源, 王寿明, 郝坤艳, 于乐成   

  1. 210002 江苏南京 东部战区总医院秦淮医疗区感染科
  • 收稿日期:2021-11-12 出版日期:2022-08-31 发布日期:2022-09-30
  • 通讯作者: 于乐成,Email:gslsycy@163.com

Clinical and liver pathological features and mutation of UGT1A1 Gene in a case with Crigler-Najjar Syndrome type Ⅱ

XU jing, DONG yuan, WANG Shou-ming, HAO Kun-yan, YU Yue-cheng   

  1. Department of Infectious,Qinhuai Medical Treatment Area,Eastern Theater General Hospital, Nanjing 210002, China
  • Received:2021-11-12 Online:2022-08-31 Published:2022-09-30
  • Contact: YU Yue-cheng,Email:gslsycy@163.com

摘要: 目的 了解Crigler-Najjar综合征Ⅱ型的遗传特点及诊断方法。方法 收集1例Crigler-Najjar综合征Ⅱ型患者的病史资料、肝脏生化、影像学结果、肝脏病理资料及本人与父母的UGT1A1的基因测序结果。结果 Crigler-Najjar综合征Ⅱ型患者的胆红素升高通常大于5倍正常值上限,为间接胆红素明显升高,ALT、AST均正常,病理未见肝细胞炎症坏死,患者为UGT1A1的基因检测示第5外显子c.1456T>G(p.Tyr486Asp)的纯合突变,其父母均为该突变的杂合子。苯巴比妥诱导治疗有效。结论 c.1456T>G(p.Tyr486Asp)的基因突变为本例患者及其家系的致病基因,患者为常染色体隐性遗传性疾病,表现为间接胆红素明显升高,肝脏无炎症损伤,苯巴比妥诱导有效。

关键词: Crigler-Najjar综合征Ⅱ型, 尿苷二磷酸葡萄糖醛酸转移酶(UGT1A1), 肝脏病理

Abstract: Objective Through analyzing the clinical, liver pathology and family uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene mutation characteristics of a patient with hereditary hyperbilirubinemia, in order to understand the genetic characteristics and diagnostic methods of Crigler-Najjar Syndrome type Ⅱ.Methods The medical history, liver biochemistry, imaging examination results, liver pathological data of a patient with Crigler-Najjar Syndrome type Ⅱ were collected, we also analyzed the UGT1A1 gene sequencing results of this patient and his parents.Results The increase of bilirubin in patients with Crigler-Najjar Syndrome type Ⅱ was usually greater than 5 times the upper limit of normal value, which was a significant increase in indirect bilirubin (IBIL). ALT and AST of the patient were normal, inflammation and necrosis of hepatocytes were seldom in hepatic pathology from the patient. The patient was a homozygous mutation in UGT1A1 gene Exon 5 c.1456T>G (p.Tyr486Asp), and heterozygotes of the mutation were found in his parents. The treatment of Phenobarbital was effective.Conclusion Missense mutation of Tyr486Asp in Exon 5 of UGT1A1 gene is the pathogenic factor of this patient with Crigler-Najjar Syndrome type Ⅱ and his family, which is autosomal recessive inheritance, with significantly increased IBIL. There is no inflammatory injury in the liver, and phenobarbital induction is effective.

Key words: Crigler-Najjar Syndrome Ⅱ, UGT1A1, Hepatic pathology